Healthlinx Launches OvPlex in UK, Heating Up Race to Get Ovarian Cancer Dx to Market

The launch in the UK by the Aussie firm follows a smaller launch in Australia as proteomics cancer diagnostics begin to make headway into the market after years of setback and false starts.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.